PTIQ | CAS#1032822-42-6 | MMP-3 production inhibitor

MedKoo Cat#: 562990 | Name: PTIQ

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PTIQ is a neuroprotective compound. It inhibits tetrahydro-L-biopterin-induced cytotoxicity and increases in matrix metalloproteinase-3 (MMP-3) levels in CATH.a cells (IC50s = 1.8 and 0.06 µM, respectively). PTIQ inhibits LPS-induced production of MMP-3, TNF-α, and COX-2 in BV-2 microglia (IC50s = 2.4, 6.5, and 9.3 µM, respectively). In vivo, PTIQ (3 and 30 mg/kg) increases survival of striatal nigral dopaminergic neurons, reduces microglial activation, and alleviates motor deficits in a mouse model of MPTP-induced Parkinson’s disease.

Chemical Structure

PTIQ

CAS#1032822-42-6

Theoretical Analysis

MedKoo Cat#: 562990

Name: PTIQ

CAS#: 1032822-42-6

Chemical Formula: C13H17NO3

Exact Mass: 235.1208

Molecular Weight: 235.28

Elemental Analysis: C, 66.36; H, 7.28; N, 5.95; O, 20.40

Price and Availability

Size	Price	Availability
25mg	USD 350.00	2 Weeks
50mg	USD 600.00	2 Weeks
100mg	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

PTIQ;

IUPAC/Chemical Name

1-(3,4-Dihydro-7-hydroxy-6-methoxy-2(1H)-isoquinolinyl)-1-propanone

InChi Key

BEDYMEDICHGLSE-UHFFFAOYSA-N

InChi Code

InChI=1S/C13H17NO3/c1-3-13(16)14-5-4-9-7-12(17-2)11(15)6-10(9)8-14/h6-7,15H,3-5,8H2,1-2H3

SMILES Code

CCC(N1CC2=C(C=C(OC)C(O)=C2)CC1)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 235.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Mautone JA, Marcelle E, Tresco KE, Power TJ. Assessing the Quality of Parent-Teacher Relationships for Students with ADHD. Psychol Sch. 2015 Feb;52(2):196-207. PubMed PMID: 25663718; PubMed Central PMCID: PMC4316369. 2: Kitanaka J, Kitanaka N, Hall FS, Uhl GR, Asano H, Chatani R, Hayata S, Yokoyama H, Tanaka KI, Nishiyama N, Takemura M. Pretreatment with nomifensine or nomifensine analogue 4-phenyl-1,2,3,4-tetrahydroisoquinoline augments methamphetamine-induced stereotypical behavior in mice. Brain Res. 2012 Feb 23;1439:15-26. doi: 10.1016/j.brainres.2011.12.043. Epub 2011 Dec 31. PubMed PMID: 22265332; PubMed Central PMCID: PMC4093904. 3: Son HJ, Lee JA, Shin N, Choi JH, Seo JW, Chi DY, Lee CS, Kim EM, Choe H, Hwang O. A novel compound PTIQ protects the nigral dopaminergic neurones in an animal model of Parkinson's disease induced by MPTP. Br J Pharmacol. 2012 Apr;165(7):2213-27. doi: 10.1111/j.1476-5381.2011.01692.x. PubMed PMID: 21951056; PubMed Central PMCID: PMC3413858. 4: Tateyama M, Nagao T, Ohta S, Hirobe M, Ono H. 4-Phenyltetrahydroisoquinoline, but not nomifensine or cocaine, inhibits methamphetamine-induced dopamine release. Eur J Pharmacol. 1993 Aug 10;240(1):51-6. PubMed PMID: 8405121. 5: Tateyama M, Ohta S, Nagao T, Hirobe M, Ono H. Inhibitory effect of 4-phenyltetrahydroisoquinoline on locomotion and dopamine release induced by micro-injection of methamphetamine into the nucleus accumbens of the rat. Neuropharmacology. 1993 Aug;32(8):761-6. PubMed PMID: 8413840. 6: Tateyama M, Ohta S, Nagao T, Hirobe M, Ono H. Effect of 4-phenyl-1,2,3,4-tetrahydroisoquinoline on ambulation induced by injection of methamphetamine into the nucleus accumbens in rats. Neuropharmacology. 1993 Mar;32(3):243-8. PubMed PMID: 8474620. 7: Siu PM, Vick JA. Studies on the mechanism of action of 1-(2-methyl-3-hydroxy-5-hydroxy-methyl-4-pyridyl)-6,7-dihydroxy-1,2,3, 4- tetrahydroisoquinoline (PTIQ) on blood pressure in the anesthetized dog. Res Commun Chem Pathol Pharmacol. 1989 Jun;64(3):421-33. PubMed PMID: 2781139. 8: Siu PM, Vick JA. Evidence for a central muscarinic action by 1-(2-methyl-3-hydroxy-5-hydroxymethyl-4-pyridyl)-6,7-dihydroxy-1,2, 3,4-tetrahydroisoquinoline in regulating blood pressure in the anesthetized dog. Arch Int Pharmacodyn Ther. 1987 Jan;285(1):43-9. PubMed PMID: 3579425. 9: Siu PM, Vick JA. Effect of a specific tetrahydroisoquinoline on the blood pressure in animals. Res Commun Chem Pathol Pharmacol. 1985 May;48(2):203-8. PubMed PMID: 4023409.